So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...

We recently published 13 Best ADR Stocks to Invest In. Sanofi (NASDAQ:SNY) is one of the best ADR stocks. Sanofi (NASDAQ:SNY) ...

ADRs, or American Depository Receipts, are the US-listed securities of foreign firms that allow investors in America to buy ...

(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.) By ...

With T-cell engagers already established as late-line therapies for certain blood cancers, Regeneron has released early data ...

Now, the company will aim to show the drug helps patients with eczema and asthma in larger, placebo-controlled trial.

Regeneron released new early data on two of its blood cancer drugs at ASH, aiming to expand treatment options for patients ...

All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ...

Kymera Therapeutics released positive clinical results for KT-621 for atopic dermatitis and other allergic diseases.

Analysts were hoping for a safety profile similar to what was achieved in Phase II but an abnormal sense of touch, called ...